Big data tells J&J that recent grads are more loyal than experienced hires

Eric Palmer The "people analytics team" at drugmaker Johnson & Johnson used big data analysis techniques on employees to figure out whether hiring people with experience ...

J&J sets up shop at Karolinska Institutet; Lilly, Zealand scrap R&D pact; Mapi raises $10M

Nick Paul Taylor In this week's EuroBiotech Report, Johnson & Johnson added another outpost to its burgeoning network of startup-scouting units. The J&J-Karolinska Institutet ...

Spurned by AstraZeneca, is Pfizer out for GlaxoSmithKline?

Damian Garde The latest market chatter is that Pfizer, rebuffed in its quest to acquire AstraZeneca last year, is taking a hard look at GlaxoSmithKline, and one analyst says it might ...

Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma

John Carroll Continuing a deal spree aimed at beefing up a weak pipeline, Pfizer has agreed to pay $ 87.5 million for a stake in the Dutch biotech AM-Pharma along with an option to ...

Surging Alexion plots a $500M splash in Ireland

Damian Garde Rare disease biotech Alexion is blueprinting a major expansion in Ireland, planning to spend €450 million ($ 500 million) and hire 200 workers over four years as ...

BMS looks to Caforio as next CEO

Alok Saboo FierceBiotech News

Zoetis, under pressure from activist investor Ackman, will offload 10 plants to cut costs

Eric Palmer Animal health leader Zoetis is using a move out of the Amgen playbook, whacking on manufacturing to cut costs and appease an aggressive activist investor. FiercePharma News

Exec pay critics bristle as Sanofi lines pockets of Viehbacher, Brandicourt

Carly Helfand Sanofi CEOs past and present are in line for big payouts after yesterday's annual meeting, as resolutions passed to line the pockets of ousted skipper Chris Viehbacher ...

Collegium swings for a $75M IPO for its abuse-proof painkiller

Damian Garde Months removed from a $ 50 million venture round, Massachusetts biotech Collegium Pharmaceutical is eyeing a $ 75 million IPO to get its abuse-deterrent take on oxycodone ...

MaxCyte buys into CAR-T with Johns Hopkins partnership

Damian Garde Maryland biotech MaxCyte is delving into the world of CAR-T treatments for cancer, teaming up with Johns Hopkins University on a preclinical program. FierceBiotech News

Atlas Venture unveils a $280M pure play biotech startup fund

John Carroll Squarely focused on seeding and nurturing biotech startups and armed with some of the best relationships in the business, Atlas Venture is unveiling a new $ 280 million ...

Medicines Co.’s cangrelor finally lines up for FDA approval

Damian Garde A panel of FDA advisers reversed its earlier derision and voted in favor of the Medicines Company's long-delayed blood thinner, spelling a likely approval for the drug ...
Page 5 of 118« First...34567...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS